Clinical-stage biotechnology company Sareum Holdings plc (AIM: SAR) announced on Monday that it has received a Notice of Allowance from the China National Intellectual Property Administration for its patent application covering certain crystalline forms of SDC-1801, a dual TYK2/JAK1 kinase inhibitor.
This development strengthens the company's intellectual property position in China for SDC-1801, which is being developed to treat a range of autoimmune diseases.
The patent, application number 2021800259993, provides protection for various crystalline forms and their preparation methods. Sareum expects the patent to be granted by the end of 2024, pending completion of formalities. Applications in other territories, including the US, Europe and Japan, are currently under review.
SDC-1801, Sareum's lead candidate, is in Phase 1a/b clinical development with an initial focus on psoriasis. The company is also advancing SDC-1802, another TYK2/JAK1 inhibitor, for potential use in cancer immunotherapy.
Anervea.ai names new chief commercial officer and board member
Avacta Group presents positive Phase 1 data for AVA6000 at ESMO Congress
ValiRx subsidiary Inaphaea signs co-marketing agreement with Spanios
Sareum Holdings secures patent allowance for SDC-1801 in China
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Alume Biosciences names new chief commercial officer
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Lilly expands manufacturing footprint in Ireland
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
Pheon Therapeutics names new independent, non-executive director